Skip to main contentSkip to main content
You have permission to edit this article.

Extracorporeal CPR Does Not Offer More Favorable Neurologic Outcome

  • Updated
  • 0
Extracorporeal CPR Does Not Offer More Favorable Neurologic Outcome

WEDNESDAY, Jan. 25, 2023 (HealthDay News) -- For patients with out-of-hospital cardiac arrest, extracorporeal cardiopulmonary resuscitation (CPR) does not improve favorable neurologic outcome compared with conventional CPR, according to a study published in the Jan. 26 issue of the New England Journal of Medicine.

Martje M. Suverein, M.D., from Maastricht University in the Netherlands, and colleagues randomly assigned patients aged 18 to 70 years with an out-of-hospital cardiac arrest who had received bystander CPR, had an initial ventricular arrhythmia, and did not have return of spontaneous circulation within 15 minutes after initiation of CPR to receive extracorporeal CPR or conventional CPR (70 and 64 patients, respectively). Survival with a favorable neurologic outcome at 30 days was assessed as the primary outcome.

The researchers found that 20 and 16 percent of patients in the extracorporeal CPR and conventional CPR groups, respectively, were alive with a favorable neurologic outcome at 30 days (odds ratio, 1.4; 95 percent confidence interval, 0.5 to 3.5; P = 0.52). The two groups had a similar number of serious adverse events reported per patient.

"Available data do not yet support the broad use of extracorporeal CPR in patients with witnessed out-of-hospital cardiac arrest," write the authors of an accompanying editorial. "Definitive evaluation of extracorporeal CPR will probably require studies on a much larger scale with robust statistical power to estimate any potential benefit of this resource-intensive strategy."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)


Originally published on, part of the TownNews Content Exchange.

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Scientists say delivering gene therapy directly to the brain holds great promise. The first brain-delivered gene therapy on the market was recently approved in Europe and the U.K. for a rare genetic disorder called AADC deficiency. It causes developmental delays and movement disorders in kids. New Jersey drugmaker PTC Therapeutics plans to seek approval for the treatment in the U.S. this year. Meanwhile, about 30 studies in the U.S. are testing gene therapy directly to the brain for other disorders, including Alzheimer’s and Parkinson’s. Challenges remain, especially with diseases caused by more than a single gene. But scientists say the evidence supporting this approach is mounting.

This year's North Carolina General Assembly session begins in earnest on Wednesday, two weeks after lawmakers met to pick leaders. While the legislature starts from scratch when each odd-numbered year begins, there should be plenty of familiar issues. They include whether to approve Medicaid expansion, medical marijuana and sports gambling. Republicans also are likely to try to enact looser gun laws and tougher immigration directives given they hold a veto-proof majority in the Senate and are just one seat short in the House. Gov. Roy Cooper and fellow Democrats aim to block more restrictive abortion rules in light of the Supreme Court ruling striking down Roe v. Wade.

A phone’s camera lens can measure a heart rate. The microphone, kept by the bedside, can screen for sleep apnea. Even the speaker is being tapped, to monitor breathing. But using smartphones as diagnostic tools is a work in progress, experts say.

President Joe Biden is expected to name the man who ran his administration’s initial response to the COVID-19 pandemic as his next chief of staff. Word of Jeff Zients' hiring comes from two people familiar with the matter who spoke to The Associated Press on condition of anonymity. Biden’s current top aide, Ron Klain, is preparing to leave the job in the coming weeks. Since his role as the administration’s COVID-19 response coordinator, Zients has returned to the White House in a low-profile position to work on staffing matters for the remainder of Biden’s first term.

Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSS Feed | Omny Studio

Get up-to-the-minute news sent straight to your device.


News Alert

Breaking News